Development & Characterization of IBI3055, a 2+1 Format, CD19 & BCMA Dual Targeting T-Cell Engager for Autoimmune Diseases
- Novel T-cell engager for autoimmune diseases
- CD19 and BCMA targeting therapies for B-cell and plasma cell depletion
- New therapeutic approaches for drug for immune resetting